View details of this raise on Seedstage

Boston, MA

Developing a decentralized diagnostic platform to enhance healthcare delivery.

• Decentralized Diagnostics: Illumicell AI’s platform enables point-of-care diagnostics, reducing reliance on centralized labs.
• Advanced Imaging Technology: The Cell Scanner offers a larger field of view and 3D imaging, improving diagnostic precision.
• AI Integration: Machine learning algorithms provide real-time, automated analysis with high accuracy.
• Broad Market Application: The technology is applicable to various fluids, expanding potential clinical markets.
• Sustainable Business Model: Revenue is generated through hardware sales and subscription-based software services.

Illumicell AI is advancing a next-generation cellular intelligence platform aimed at decentralizing diagnostic testing. The company is addressing the limitations of centralized laboratories, which are often slow, costly, and dependent on specialized staff. By leveraging scalable imaging modules and cloud computing, Illumicell AI enables point-of-care diagnostics, allowing clinicians to make earlier decisions and improve patient outcomes. The initial focus is on male fertility, where traditional testing can take up to eight weeks and cost $450 per test. Illumicell AI’s technology reduces these delays, enhancing clinical decision-making and patient care.

The company’s platform combines a novel imaging scanner with advanced machine learning algorithms to deliver accurate and scalable diagnostics. The lens-free Cell Scanner, integrated with AI, provides real-time, automated analysis without the need for specialized staffing. This approach not only lowers operational costs but also expands access to broader clinical markets, including urine and blood analysis. Illumicell AI’s business model includes hardware sales bundled with a subscription-based software service, offering recurring revenue streams. The company is supported by a network of clinical experts and business leaders, ensuring robust scientific credibility and market demand for its innovative diagnostic solutions.

Company Info

Illumicell AI develops a decentralized diagnostic platform using advanced imaging and AI to improve healthcare outcomes.

Illumicell AI is developing a next-generation cellular intelligence platform that decentralizes diagnostic testing, bringing it directly to the point of care. By integrating a novel imaging scanner with advanced machine learning algorithms, the company offers a highly accurate and scalable diagnostic tool that eliminates the need for centralized laboratories. This approach addresses the inefficiencies of traditional diagnostic testing, which is often slow, costly, and dependent on specialized staff, by providing real-time, automated analysis with consistently high accuracy.

The platform’s initial focus is on semen analysis, but its technology is applicable to a wide range of fluids, including urine and blood, opening access to broader clinical markets. Illumicell AI’s solution is designed to improve patient outcomes by enabling earlier clinical decisions and reducing operational costs. The company employs a SaaS model, generating revenue through hardware sales bundled with a subscription-based software service, which supports recurring income streams and strong gross margins.